Inhibition of carboxylesterase-1 alters clopidogrel metabolism and disposition

References

• Amsterdam EA, Wenger NK, Brindis RG, et al. (2014). 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 130:e344–426.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Jakubowski JA, Ferreiro JL, et al. (2014). Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol 64:1005–14.
   PubMed Web of Science ®Google Scholar
• Bahar FG, Ohura K, Ogihara T, Imai T. (2012). Species difference of esterase expression and hydrolase activity in plasma. J Pharm Sci 101:3979–88.
   PubMed Web of Science ®Google Scholar
• Busby WF, Jr., Ackermann JM, Crespi CL. (1999). Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 27:246–9.
   PubMed Web of Science ®Google Scholar
• Fan W, Plent S, Prats J, Deliargyris EN. (2016). Trends in P2Y12 inhibitor use in patients referred for invasive evaluation of coronary artery disease in contemporary US practice. Am J Cardiol 117:1439–43.
   PubMed Web of Science ®Google Scholar
• Gong IY, Crown N, Suen CM, et al. (2012). Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. Eur Heart J 33:2856–64.
   PubMed Web of Science ®Google Scholar
• Hu ZY, Laizure SC, Herring VL, Parker RB. (2014). Identification of alcohol-dependent clopidogrel metabolites using conventional liquid chromatography/triple quadrupole mass spectrometry. Rapid Commun Mass Spectrom 28:1285–92.
   PubMed Web of Science ®Google Scholar
• Kazui M, Nishiya Y, Ishizuka T, et al. (2010). Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38:92–9.
   PubMed Web of Science ®Google Scholar
• Laizure SC, Herring VL, Hu Z, et al. (2013). The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy 33:210–22.
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Price LH, McDougle CJ, et al. (1993). Concurrent cocaine-ethanol ingestion in humans: pharmacology, physiology, behavior, and the role of cocaethylene. Psychopharmacology (Berl) 111:39–46.
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. (2009). Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354–62.
   PubMed Web of Science ®Google Scholar
• Mega JL, Simon T, Collet JP, et al. (2010). Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304:1821–30.
   PubMed Web of Science ®Google Scholar
• Morton CL, Iacono L, Hyatt JL, et al. (2005). Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemother Pharmacol 56:629–36.
   PubMed Web of Science ®Google Scholar
• Morton CL, Wierdl M, Oliver L, et al. (2000). Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. Cancer Res 60:4206–10.
   PubMed Web of Science ®Google Scholar
• Parker RB, Hu ZY, Meibohm B, Laizure SC. (2015). Effects of alcohol on human carboxylesterase drug metabolism. Clin Pharmacokinet 54:627–38.
   PubMed Web of Science ®Google Scholar
• Patrick KS, Straughn AB, Minhinnett RR, et al. (2007). Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 81:346–53.
   PubMed Web of Science ®Google Scholar
• Samant S, Jiang XL, Peletier LA, et al. (2017). Identifying clinically relevant sources of variability: the clopidogrel challenge. Clin Pharmacol Ther 101:264–73.
   PubMed Web of Science ®Google Scholar
• Savi P, Pereillo JM, Uzabiaga MF, et al. (2000). Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84:891–6.
   PubMed Web of Science ®Google Scholar
• Sherwood MW, Melloni C, Jones WS, et al. (2015). Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J Am Heart Assoc 4. Available from: https://doi.org/10.1161/JAHA.115.002245
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O'Connell JR, Bliden KP, et al. (2009). Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849–57.
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Trenk D, Schror K, et al. (2013). Response variability to P2Y12 receptor inhibitors: expectations and reality. JACC Cardiovasc Interv 6:1111–28.
   PubMed Web of Science ®Google Scholar
• Soares ER. (1979). Identification of a new allele of Es-I segregating in an inbred strain of mice. Biochem Genet 17:577–83.
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Weisz G, et al. (2013). Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382:614–23.
   PubMed Web of Science ®Google Scholar
• Tang M, Mukundan M, Yang J, et al. (2006). Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 319:1467–76.
   PubMed Web of Science ®Google Scholar
• Tarkiainen EK, Holmberg MT, Tornio A, et al. (2015). Carboxylesterase 1 c.428G > A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. Clin Pharmacol Ther 97:650–8.
   PubMed Web of Science ®Google Scholar
• Tuffal G, Roy S, Lavisse M, et al. (2011). An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma. Thromb Haemost 105:696–705.
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Appel DI, Peterson YK, et al. (2010). Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions. Toxicology 270:59–65.
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Wang X, Gawronski BE, et al. (2013). Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther 344:665–72.
   PubMed Web of Science ®Google Scholar